Image pharmaphorum Editor News Roche buys Tusk, plus cancer immunotherapy drug, for £62m Roche has bought immuno-oncology biotech firm Tusk Therapeutics for an upfront payment of £62 million. News US regulator backs Pfizer's Vizimpro lung cancer drug The US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients whose tumours have a certain mutation. News Australians still concerned as My Health Record row continue... The controversial Australian data scheme, My Health Record, continues to spark mixed reactions and uncertainty from professionals and the public. News Ipsen strengthens oncology R&D team with two experts French pharma company Ipsen has hired two R&D leaders to boost the company’s oncology arm. Load more results
News Roche buys Tusk, plus cancer immunotherapy drug, for £62m Roche has bought immuno-oncology biotech firm Tusk Therapeutics for an upfront payment of £62 million.
News US regulator backs Pfizer's Vizimpro lung cancer drug The US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients whose tumours have a certain mutation.
News Australians still concerned as My Health Record row continue... The controversial Australian data scheme, My Health Record, continues to spark mixed reactions and uncertainty from professionals and the public.
News Ipsen strengthens oncology R&D team with two experts French pharma company Ipsen has hired two R&D leaders to boost the company’s oncology arm.
News Head-to-head trial dents Novo Nordisk's obesity hopes Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
